Gilead Purchases FDA Priority Review Voucher For $125M
NPR: Gilead Buys Shortcut For FDA Drug Review For $125 Million
“…In an auction, Gilead Sciences, a maker of HIV and hepatitis medicines, just bought a coupon good for the accelerated review of a drug of the company’s choice from Knight Therapeutics, a Canadian company. The priority review voucher entitles Gilead to move a drug of its choice through the FDA four months faster than the normal track. … The legal shortcut was created in 2007 as a reward for companies developing drugs for specific neglected tropical diseases…” (Hensley, 11/19).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.